Skip to main content
. 2020 Oct 6;161(4):345–353. doi: 10.1111/imm.13254

Figure 1.

Figure 1

Flow cytometric characterization of myeloid cell subsets in COVID‐19 patients. (A) Absolute numbers of platelets (P), neutrophils (N), lymphocytes (L), monocytes (M), basophils (B) and eosinophils (E) in healthy subjects (black dots) and COVID‐19 patients (grey dots). (B) Absolute numbers of plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells cDC2 in healthy subjects (black dots) and COVID‐19 patients (grey dots). (C) CD64, CD11b and HLA‐DR antigen expression on monocytes in healthy subjects (black dots) and COVID‐19 patients (grey dots). (D) Monocyte subset distribution in healthy subjects and COVID‐19 patients. Stacked columns represent means of CD14++/CD16− in orange, CD14++/CD16+ in green and CD14+/CD16++ in violet. *P ≤ 0.05, calculated with Student’s t‐test, referred to CD14+/CD16++ subset. (E) CD64, CD11b and CD66b antigen expression on neutrophils in healthy subjects (black dots) and COVID‐19 patients (grey dots). Data have been obtained from eight healthy controls and 40 COVID‐19 patients. *P ≤ 0.05, calculated with Student’s t‐test.